Remdesivir and Tocilizumab, two key drugs being used for the treatment of hospitalised COVID-19 patients, are difficult to find in most parts of the country. The demand is huge and the stocks are scarce. There are also reports that Remdesivir, which costs around Rs 4,000, is being sold for as much as Rs 50,000 in the black market. Recently, a Parliamentary panel also expressed concern over the rampant black marketing of Remdesivir and Tocilizumab, which are part of India's approved clinical management protocol for Covid-19.